Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2012

Document Sample
Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2012 Powered By Docstoc
					    Onychomycosis (Tinea Unguium) – Pipeline Review,
                       H1 2012


                                                                                          Reference Code: GMDHC1853IDB
                                                                                             Publication Date: March 2012




Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2012                                    GMDHC1853IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                           Page(1)
Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 5
    List of Figures ................................................................................................................................................................................ 6
Introduction......................................................................................................................................................................................... 7
    Global Markets Direct Report Coverage ........................................................................................................................................ 7
Onychomycosis (Tinea Unguium) Overview....................................................................................................................................... 8
Therapeutics Development................................................................................................................................................................. 9
    An Overview of Pipeline Products for Onychomycosis (Tinea Unguium) ...................................................................................... 9
Onychomycosis (Tinea Unguium) Therapeutics under Development by Companies ....................................................................... 11
Late Stage Products ......................................................................................................................................................................... 14
    Comparative Analysis .................................................................................................................................................................. 14
Mid Clinical Stage Products.............................................................................................................................................................. 15
    Comparative Analysis .................................................................................................................................................................. 15
Early Clinical Stage Products ........................................................................................................................................................... 16
    Comparative Analysis .................................................................................................................................................................. 16
Pre-Clinical Stage Products.............................................................................................................................................................. 17
    Comparative Analysis .................................................................................................................................................................. 17
Onychomycosis (Tinea Unguium) Therapeutics – Products under Development by Companies ..................................................... 18
Companies Involved in Onychomycosis (Tinea Unguium) Therapeutics Development.................................................................... 19
    Valeant Pharmaceuticals International ........................................................................................................................................ 19
    Dr. Reddy's Laboratories Limited................................................................................................................................................. 20
    Bayer AG ..................................................................................................................................................................................... 21
    Helix BioMedix, Inc. ..................................................................................................................................................................... 22
    NexMed, Inc. ............................................................................................................................................................................... 23
    NovaBay Pharmaceuticals, Inc. ................................................................................................................................................... 24
    Hisamitsu Pharmaceutical Co., Inc. ............................................................................................................................................. 25
    Evolva SA .................................................................................................................................................................................... 26
    Novabiotics Ltd ............................................................................................................................................................................ 27
    Anacor Pharmaceuticals, Inc. ...................................................................................................................................................... 28
    Topica Pharmaceuticals Inc......................................................................................................................................................... 29
    Nitric Biotherapeutics, Inc. ........................................................................................................................................................... 30
    NanoBio Corporation ................................................................................................................................................................... 31
    Promius Pharma, LLC ................................................................................................................................................................. 32
    Moberg Derma AB ....................................................................................................................................................................... 33
    Celtic Pharmaceutical Holdings L.P............................................................................................................................................. 34
    Mayne Pharma Limited ................................................................................................................................................................ 35
Onychomycosis (Tinea Unguium) – Therapeutics Assessment ....................................................................................................... 36
    Assessment by Monotherapy Products ....................................................................................................................................... 36
    Assessment by Route of Administration ...................................................................................................................................... 37
    Assessment by Molecule Type .................................................................................................................................................... 39
Drug Profiles..................................................................................................................................................................................... 41
    HB1275 - Drug Profile ................................................................................................................................................................. 41



Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2012                                                                                        GMDHC1853IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2012




        Product Description................................................................................................................................................................. 41
        Mechanism of Action ............................................................................................................................................................... 41
        R&D Progress ......................................................................................................................................................................... 41
    TDT-067 - Drug Profile ................................................................................................................................................................ 42
        Product Description................................................................................................................................................................. 42
        Mechanism of Action ............................................................................................................................................................... 42
        R&D Progress ......................................................................................................................................................................... 42
    MycoVa - Drug Profile ................................................................................................................................................................. 43
        Product Description................................................................................................................................................................. 43
        Mechanism of Action ............................................................................................................................................................... 43
        R&D Progress ......................................................................................................................................................................... 43
    EV-086 - Drug Profile .................................................................................................................................................................. 45
        Product Description................................................................................................................................................................. 45
        Mechanism of Action ............................................................................................................................................................... 45
        R&D Progress ......................................................................................................................................................................... 45
    Luliconazole - Drug Profile .......................................................................................................................................................... 46
        Product Description................................................................................................................................................................. 46
        Mechanism of Action ............................................................................................................................................................... 46
        R&D Progress ......................................................................................................................................................................... 46
    IDP-108 - Drug Profile ................................................................................................................................................................. 47
        Product Description................................................................................................................................................................. 47
        Mechanism of Action ............................................................................................................................................................... 47
        R&D Progress ......................................................................................................................................................................... 47
    NVC-612 - Drug Profile................................................................................................................................................................ 48
        Product Description................................................................................................................................................................. 48
        Mechanism of Action ............................................................................................................................................................... 48
        R&D Progress ......................................................................................................................................................................... 48
    Bifonazole Cream - Drug Profile .................................................................................................................................................. 49
        Product Description................................................................................................................................................................. 49
        Mechanism of Action ............................................................................................................................................................... 49
        R&D Progress ......................................................................................................................................................................... 49
    Tavaborole - Drug Profile ............................................................................................................................................................ 50
        Product Description................................................................................................................................................................. 50
        Mechanism of Action ............................................................................................................................................................... 50
        R&D Progress ......................................................................................................................................................................... 50
    AN2718 - Drug Profile ................................................................................................................................................................. 51
        Product Description................................................................................................................................................................. 51
        Mechanism of Action ............................................................................................................................................................... 51
        R&D Progress ......................................................................................................................................................................... 51
    NB-002 - Drug Profile .................................................................................................................................................................. 52
        Product Description................................................................................................................................................................. 52
        Mechanism of Action ............................................................................................................................................................... 52
        R&D Progress ......................................................................................................................................................................... 52
    SUBACAP - Drug Profile ............................................................................................................................................................. 53


Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2012                                                                                    GMDHC1853IDB / Pub March 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                              Page(3)
Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2012




        Product Description................................................................................................................................................................. 53
        Mechanism of Action ..........................
				
DOCUMENT INFO
Description: Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2012, provides an overview of the Onychomycosis (Tinea Unguium) therapeutic pipeline. This report provides information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium). 'Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries